Search Bar & Filters
Found 2056 Actively Recruiting clinical trials
Actively Recruiting
Pneumonia is a common and serious infection in patients receiving Veno-arterial Extracorporeal Membrane Oxygenation ECMO-VA, with a high rate of treatment failure despite tailored antibiotic therapy. This study explores whether nebulized amikacin can improve bacterial clearance and reduce treatment failure or recurrence of gram-negative bacilli pneumonia during mechanical ventilation in these patients. Participants in this randomized trial will either receive inhaled amikacin by nebulization at a dose of 25 mgkg once daily for 5 days alongside standard care, or standard care alone without nebulization. The treatment begins within 6 hours of randomization. The study focuses on comparing the effectiveness of nebulized amikacin plus standard care versus standard care alone in this specific patient group. During the study, researchers will monitor bacterial eradication rates by Day 5 as the primary outcome, along with clinical cure, pneumonia persistence, pulmonary infection scores, aeration scores, adverse events, and pharmacokinetic analyses of amikacin and piperacillin-tazobactam. Patients must be on mechanical ventilation and have confirmed gram-negative ventilator-associated pneumonia. Safety and treatment responses will be closely assessed during the 5-day treatment period.
Actively Recruiting
Researchers are evaluating the use of early near apneic ventilation compared to usual ultra-protective lung ventilation in patients with severe acute respiratory distress syndrome ARDS who are supported by venovenous extracorporeal membrane oxygenation ECMO. The trial, named CALMDOWN, is a prospective, open-label, multicenter, randomized controlled study aiming to investigate whether early apneic ventilation can help reduce ventilator-induced lung injury, ECMO duration, and mortality by day 60 in this critically ill population. Participants are randomly assigned to one of two groups one group receives near apneic ventilation during the first 3 days of ECMO using BIPAPAPRV or pressure-controlled ventilation with specific settings to maintain airway pressure and minimize ventilation rate. Neuromuscular blockade and sedation may be used as needed. After 3 days, apneic ventilation may continue or switch to ultra-protective lung ventilation at the physicians discretion. The other group receives standard ultra-protective lung ventilation throughout ECMO support with defined ventilator settings. Prone positioning is allowed in both groups based on physician judgment. During the study, participants will be monitored closely for outcomes including mortality at day 60, need for lung transplantation, persistence of ECMO support, and days alive without ECMO from day 0 to day 60. Additional assessments cover mortality and other clinical outcomes up to day 90, duration of ventilation, ICU stay, hospital stay, and complications such as pneumonia, pneumothorax, and right ventricular function. The trial is sponsored by Assistance Publique - Hpitaux de Paris and runs until May 2030.
Actively Recruiting
This multicenter interventional study evaluates the progression of coronary artery disease over 5 years in adults aged 30 to 60 years with genetically confirmed heterozygous familial hypercholesterolemia HeFH. The study addresses challenges in cardiovascular risk assessment for HeFH patients, focusing on both calcified and non-calcified plaques using advanced imaging techniques. It aims to better understand plaque burden changes and classify coronary stenosis using the CAD-RADS v2.0 system, comparing baseline data from 2018-2022 with current findings. Participants undergo coronary computed tomography angiography CCTA with iodinated contrast to visualize coronary arteries. The study includes 300 patients divided into protected and non-protected groups based on their clinical characteristics. Individual participation lasts from one day up to one week, with the overall study period spanning 2 years. Extended follow-up for up to 10 years will use routinely collected medical data to monitor cardiovascular events and disease progression. During the study visit, participants receive detailed imaging assessments, clinical exams, and questionnaires measuring health status and cardiovascular risk factors. Researchers measure coronary plaque volume, lesion types, calcium scores, arterial dimensions, and other biomarkers. They also evaluate quality of life and symptoms using validated surveys. Safety and cardiovascular events are tracked through long-term medical record review. This comprehensive evaluation helps identify changes in coronary artery disease and related health outcomes over time.
Actively Recruiting
This research aims to improve early diagnosis and classification of rheumatic diseases, which affect bones and joints. Rheumatic diseases are typically diagnosed using clinical signs, biological tests, and imaging, but in about 20% of cases, the diagnosis remains unclear, delaying treatment. Conventional methods may lack sensitivity and specificity for early detection, so the study explores novel biomarkers from biological samples to assist diagnosis and patient classification. The study collects biological samples such as synovial fluid via joint aspiration, blood through venous puncture, and tissue samples during surgery, which are part of routine patient care. These samples will be analyzed using both conventional laboratory tests like histology, immunodetection, and PCR, as well as innovative techniques such as Raman spectroscopy and nanospectroscopy. The investigators aim to detect new biomarkers that can better characterize rheumatic diseases and their progression. Participants provide samples during their routine care procedures, and researchers analyze the chemical, biological, and protein changes in these samples using advanced laboratory methods. The primary outcomes include spectral analysis of tissues and biofluids with surface-enhanced Raman spectroscopy, and protein and RNA expression using immunodetection and PCR techniques. This observational study involves ongoing data collection until 2029, with no direct intervention beyond sample collection during standard medical procedures.
Actively Recruiting
Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
This research aims to evaluate antibiotic treatments for acute pyelonephritis AP in children aged 1 month to 3 years. It compares a shorter intravenous IV antibiotic course of 3 days alone to a longer treatment consisting of 3 days IV followed by 7 days of oral antibiotics. The goal is to see if the shorter IV treatment is as effective in curing AP and preventing recurrence and renal scarring, while reducing the risk of antibiotic resistance and preserving gut microbiota diversity. Participants are randomly assigned to one of two groups. The experimental group receives only 3 days of IV antibiotics with ceftriaxone andor amikacin, after which treatment is stopped. The control group receives the usual care of 3 days IV antibiotics followed by 7 days of oral antibiotics, either cotrimoxazole or cefixime. The study includes collection of fecal or rectal swabs and blood tests to assess microbiota and resistance. Treatment effectiveness and safety are compared between groups. During the study, children are monitored for fever, symptoms, and urine cultures to confirm infection clearance. Researchers measure recurrence of febrile urinary tract infections within 28 days after treatment ends and follow clinical cure at 10 or 17 days depending on the group. Additional assessments include monitoring recurrence at 90 days, antimicrobial resistance in gut bacteria, and intestinal microbiota diversity over about a month. Participation lasts through treatment and follow-up visits up to several weeks.
Actively Recruiting
Researchers are investigating the relationship between left ventricular LV myocardial stiffness and myocardial interstitial fibrosis in people with primary mitral regurgitation MR, a common heart valve disease that can lead to heart failure. The study aims to evaluate how 3D ultrasound measurements of mechanical wave velocity MWV in the heart muscle relate to fibrosis measured by cardiac magnetic resonance imaging CMR. Participants will undergo routine tests including 2D and 3D echocardiography with MWV imaging, CMR scans, 24-hour electrocardiogram monitoring, blood tests including brain natriuretic peptide levels, and symptom-limited exercise echocardiography with oxygen uptake measurements. This observational study involves no treatment but collects detailed imaging and clinical data to better understand myocardial stiffness and fibrosis. During the study, patients will have comprehensive heart imaging and monitoring to assess heart function and stiffness. Researchers will measure correlations between LV stiffness and myocardial fibrosis, as well as links to clinical stages of MR, LV mass, and heart strain. The primary outcome is the correlation between LV stiffness assessed by 3D MWV and fibrosis measured by CMR extracellular volume. The study starts in October 2024 and continues through November 2027.
Actively Recruiting
Healthy Volunteer
The trial compares the time taken to record a complete Electrocardiogram ECG using a novel 4-electrode tablet device called DigitalCardio CardioSecur4 with a standard 12-lead ECG device in adults with cardiac conditions. It aims to determine differences in recording time, trace quality, and healthcare professional satisfaction between the two ECG methods. The study uses a randomized, crossover design with hospitalized and outpatient cardiology patients who are hemodynamically stable and able to consent. Participants are randomly assigned to one of two groups Group A undergoes the standard 10-electrode ECG first followed immediately by the 4-electrode DigitalCardio ECG, while Group B receives the DigitalCardio ECG first followed by the standard ECG. Both ECG recordings are performed by the same operator within a short interval to ensure consistency. Anonymized ECG traces are assessed independently for quality, diagnostic parameters, and any missing or erroneous leads. During the trial, researchers measure the total time from electrode placement to complete ECG trace capture for each device. Healthcare professionals complete a questionnaire to evaluate their satisfaction with the DigitalCardio system. The study includes initial screening for eligibility and informed consent. Outcome measures include procedure time comparison, trace quality, diagnostic concordance, user satisfaction, and technical incident rates. The trial is conducted in a single day per participant with no long-term follow-up.
Actively Recruiting
Researchers are studying portal hypertension, a major cause of liver complications such as ascites, variceal bleeding, and hepatic encephalopathy in patients with cirrhosis. This diagnostic study compares the current invasive measurement method, hepatic venous pressure gradient HVPG, with a newer non-invasive imaging technique called 4D-flow MRI. The goal is to validate 4D-flow MRI as a reliable alternative to invasive testing and to assess its ability to predict complications and outcomes after transjugular intrahepatic portosystemic shunt TIPS procedures. The study involves 60 adult patients divided into two groups one with compensated cirrhosis related to metabolic dysfunction-associated steatotic liver disease MASLD and another with decompensated cirrhosis undergoing TIPS placement. MASLD group participants will receive invasive HVPG measurements and 4D-flow MRI with gadolinium contrast, while the TIPS group will have 4D-flow MRI scans before and after the TIPS procedure along with invasive pressure measurements. Blood samples will be collected for advanced biological analyses. Participants will be followed for 6 months to monitor portal hypertension-related events, including ascites, bleeding, encephalopathy, and liver-related death. The study will measure correlations between invasive pressure readings and 4D-flow MRI parameters, as well as biological markers related to complications. This research aims to improve patient selection for TIPS and reduce the need for invasive procedures by using advanced imaging and multi-omics profiling.
1-10 of 2,056
1